Novolog (Pharm-Up 1966) Ltd

TASE:NVLG Stock Report

Market Cap: ₪878.9m

Novolog (Pharm-Up 1966) Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Novolog (Pharm-Up 1966).

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth18.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Estimating The Fair Value Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG)

Nov 05
Estimating The Fair Value Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG)

Be Wary Of Novolog (Pharm-Up 1966) (TLV:NVLG) And Its Returns On Capital

Jul 25
Be Wary Of Novolog (Pharm-Up 1966) (TLV:NVLG) And Its Returns On Capital

I Ran A Stock Scan For Earnings Growth And Novolog (Pharm-Up 1966) (TLV:NVLG) Passed With Ease

May 07
I Ran A Stock Scan For Earnings Growth And Novolog (Pharm-Up 1966) (TLV:NVLG) Passed With Ease

Read This Before Buying Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) For Its Dividend

Apr 14
Read This Before Buying Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) For Its Dividend

Novolog (Pharm-Up 1966)'s (TLV:NVLG) Earnings Are Of Questionable Quality

Mar 24
Novolog (Pharm-Up 1966)'s (TLV:NVLG) Earnings Are Of Questionable Quality

Novolog (Pharm-Up 1966) Ltd's (TLV:NVLG) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 09
Novolog (Pharm-Up 1966) Ltd's (TLV:NVLG) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

How Much Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) Do Insiders Own?

Feb 15
How Much Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) Do Insiders Own?

Update: Novolog (Pharm-Up 1966) (TLV:NVLG) Stock Gained 88% In The Last Three Years

Jan 25
Update: Novolog (Pharm-Up 1966) (TLV:NVLG) Stock Gained 88% In The Last Three Years

How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?

Dec 29
How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?

With EPS Growth And More, Novolog (Pharm-Up 1966) (TLV:NVLG) Is Interesting

Dec 08
With EPS Growth And More, Novolog (Pharm-Up 1966) (TLV:NVLG) Is Interesting

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Novolog (Pharm-Up 1966) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TASE:NVLG - Analysts future estimates and past financials data (ILS Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20241,728-644104N/A
6/30/20241,683-18-1249N/A
3/31/20241,668-2086153N/A
12/31/20231,643-42129200N/A
9/30/20231,63015177252N/A
6/30/20231,59724222295N/A
3/31/20231,5462566145N/A
12/31/20221,5084863133N/A
9/30/20221,4244379137N/A
6/30/20221,3664372121N/A
3/31/20221,3154169101N/A
12/31/20211,255425383N/A
9/30/20211,229412147N/A
6/30/20211,190403258N/A
3/31/20211,148404167N/A
12/31/20201,134403358N/A
9/30/20201,08538-720N/A
6/30/20201,06124-30-4N/A
3/31/20201,042183964N/A
12/31/20191,0041076101N/A
9/30/20191,0009134157N/A
6/30/201996318144165N/A
3/31/2019943224976N/A
12/31/201891023-524N/A
9/30/2018912221048N/A
6/30/201889123N/A79N/A
3/31/201886222N/A47N/A
12/31/201783923N/A86N/A
9/30/201779723N/A20N/A
6/30/201778024N/A33N/A
3/31/201777027N/A-8N/A
12/31/201673929N/A20N/A
9/30/201673028N/A151N/A
12/31/201568325N/A140N/A
12/31/201462924N/A161N/A
12/31/201354315N/A-56N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NVLG's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if NVLG's earnings are forecast to grow faster than the IL market

High Growth Earnings: Insufficient data to determine if NVLG's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if NVLG's revenue is forecast to grow faster than the IL market.

High Growth Revenue: Insufficient data to determine if NVLG's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NVLG's Return on Equity is forecast to be high in 3 years time


Discover growth companies